AzTrials
AzTrials

Tympanic Membrane PerforationNCT01958749

Fat Graft Myringoplasty With and Without Platelet Rich Plasma (PRP) for Treating Smaller Tympanic Membrane Perforations

A study testing Fat graft with Platelet Rich Plasma in people with Tympanic Membrane Perforation, run by Nova Scotia Health Authority at 4 sites in 2 countries.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

The current standard treatment for chronic tympanic membrane perforations (TMP) involves having fat grafted from the patient and inserted into the ear, through the perforation, to promote healing using the fat graft myringoplasty (FGM) technique. Read more about this study

Who is it for?
Ages 19 years and older
Conditions the study is for
Tympanic Membrane Perforation
What is being tested?
Fat graft with Platelet Rich Plasma
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
4 sitesin 2 countries
Study dates
1 Mar 2015to 1 Mar 2015
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Tympanic membrane perforation measuring <50% of the area of the membrane
  • Perforation present for at least 6 months (based on history or direct observation)
  • All edges of perforation are visible

Who cannot join

  • Active ear infection at the time of the procedure
  • cholesteatoma present
  • Patients on immunosuppressive therapy (including oral steroids) or chemotherapy
  • Patients with previous failed attempt at perforation repair

Trial locations and contacts

4 sites in 2 countries.

4 sites in 2 countries

Canada2 sites
  • ENT department, Victoria General Hospital

    Halifax, Nova Scotia, B3H 2Y9

  • Providence Health St Paul's Hospital

    Vancouver, British Columbia

Other trials in Canada

United Kingdom2 sites
  • Derriford Hospital

    Plymouth, Devon

  • University Hospital North Staffordshire

    Stoke-on-Trent

Other trials in United Kingdom

About this study

Official title: Efficacy of Fat Graft Myringoplasty Versus Fat Plus Platelet Rich Plasma (PRP) Myringoplasty in Closing Smaller Tympanic Membrane Perforations in an Outpatient Setting: a Randomized Study

The current standard treatment for chronic tympanic membrane perforations (TMP) involves having fat grafted from the patient and inserted into the ear, through the perforation, to promote healing using the fat graft myringoplasty (FGM) technique. Platelet rich plasma (PRP) has also been used to promote TMP healing and involves having the patient provide a blood sample, which is processed to produce PRP and applied to the perforation. This prospective, multi-centre study will evaluate whether combining both these techniques can improve the rate of closure in patients with chronic TMP involving <50% of the membrane.

Patients will be randomized to receive either the standard FGM treatment or FGM treatment with the addition of PRP. At 3 months postintervention a blinded observer will rate the degree of TMP closure. Differences in closure rates between the 2 groups will be compared.

Read the detailed description

This will be a multi-centre, single-blinded, randomised control trial. Patients will be randomised at each site to undergo FGM with or without PRP.

Step 1 in both groups is the same. Under LA (or GA if the patient is unable to tolerate this), a fat graft is taken from just behind the mastoid process, or more posteriorly just beneath the hairline if necessary. The graft is kept moist in 0.9% saline.The ear canal is injected with LA and the edges of the perforation are freshened. Gelfoam is placed into the middle ear and the fat graft placed on top of this until it touches the underside of the TM and slightly bulges through. In an attempt to achieve standardisation of surgical technique between sites, surgeons will be provided with an operative video to watch beforehand.

Step 2. The surgeon is informed of the randomisation outcome into Group 1 or 2. Group 1 (Non PRP): patients will have FGM alone, and this will simply be covered with a piece of saline-soaked Gelfoam cut to completely cover the perforation and graft.

Group 2 (PRP): as for Group 1, but the Gelfoam will instead be soaked in PRP derived from the patient's own whole blood. The generation of PRP is descibed below: -

  • 10-20 mL of autologous blood collected from an antecubital vein is placed in an adenosine citrate dextrose-acid (ACD-A) collection tube to prevent premature activation
  • Blood immediately placed in the centrifuge at 1100g for 10 minutes (once)
  • Supernatant removed and collected into syringe
  • Injected onto surface of fat graft
  • Rest added to piece of gelfoam
  • Place gelfoam + PRP on the TM perforation

Post op care: patients will be asked to keep their ear dry, and cover it with a cotton ball when taking a shower or bathing for the first week, but otherwise to leave it open. They will be given an eye dropper, and instructed to use 2 drops of white vinegar in the ear three times a day for 10 days, with the head tilted over to allow the vinegar to reach the fat graft. Vinegar drops are an effective treatment for Pseudomonas infection, the most common infection in the external ear canal, and are commonly used in external ear infections. If this causes any discomfort, the patients will be instructed to stop this, and this information will be recorded at first follow up. If there is infected discharge, the patient will be instructed to contact the surgeon, and will be treated with ciprofloxacin-containing eardrops for one week. The occurrence of such an event will be recorded, but will not be a censoring event for the purposes of the study.

Follow up schedule: Patients will be followed at 2 weeks, 6 weeks and 3 months post surgery.

A planned interim analysis will be performed at the half-way point of the study; each centre will be compared for heterogeneity with the other sites using ANOVA, for both group 1 and group 2. Data from sites with heterogeneous data may be discarded, and/or other sites recruited, and/or existing site enrollments increased as needed to allow adequate patient recruitment.

Our primary outcome measure will be tested with an unpaired t-test between the two groups. The investigators will also perform secondary analyses of the degree of closure in the non-complete closure populations between the two treatment arms using Wilcoxon non-parametric testing

Power analysis: the investigators have deemed a 30% difference in closure rate between the two groups as clinically significant. The investigators estimate the closure rate for the fat alone to be 50%, based on previous publications. To show a difference of closure rate of 70% in the blood treated group, with a power of 0.8 and an alpha error of 0.05 would require 45 subjects in each group. This is for a binary outcome of pass fail. The investigators anticipate some drop out, because of failure of follow up, in the order of 30% at 3 months, and so aim to recruit 46 subjects in each arm.

Being tested
Fat graft with Platelet Rich Plasma
Medical subject headings
Tympanic Membrane Perforation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Fat graft with Platelet Rich PlasmaProcedure or surgery

Study groups in NCT01958749
Study groupRoleWhat they receive
Fat graft without Platelet Rich PlasmaNo interventionStep 1. Under Local Anaesthetic (or General Anaesthetic if the patient is unable to tolerate this), a fat graft is taken from just behind the mastoid process, or more posteriorly just beneath the hairline if necessary. The graft is kept moist in 0.9% saline.The ear canal is injected with local anaesthetic and the edges of the perforation are freshened. Gelfoam is placed into the middle ear and the fat graft placed on top of this until it touches the underside of the TM and slightly bulges through. In an attempt to achieve standardisation of surgical technique between sites, surgeons will be provided with an operative video to watch beforehand. Step 2. The fat graft will simply be covered with a piece of saline-soaked Gelfoam cut to completely cover the perforation and graft.
Fat graft with Platelet Rich PlasmaExperimentalProcedure as for as for Fat graft without PRP, but at Step 2 the Gelfoam will instead be soaked in PRP derived from the patient's own whole blood. The generation of PRP is descibed below: - * 10-20 mL of autologous blood collected from an antecubital vein is placed in an adenosine citrate dextrose-acid (ACD-A) collection tube to prevent premature activation * Blood immediately placed in the centrifuge at 1100g for 10 minutes (once) * Supernatant removed and collected into syringe * Injected onto surface of fat graft * Rest added to piece of gelfoam * Place gelfoam + PRP on the TM perforation
Receives: Procedure: Fat graft with Platelet Rich Plasma

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Presence or absence of tympanic membrane perforation

    Measured: 3 months

Secondary outcomes (3)
  1. Degree of perforation closure

    4 Groups: Total, almost complete (very small residual perforation), substantial (>50% closure), partial (<50% closure)

    Measured: 3 months

  2. Infection rate

    Infection measured by presence of mucopurulent discharge from operated ear

    Measured: 3 months

  3. Discomfort on using vinegar drops

    Measured: 2 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Oct 2013 (estimated)
  2. Study start1 Mar 2015
  3. Primary completion1 Mar 2015
  4. Study completion1 Mar 2015

Why it stopped: REB approval was never issued

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01958749
Sponsor's protocol ID
CDHA/Fat Graft Myringoplasty
Status last verified
Sep 2013
First submitted
7 Oct 2013
Last updated
21 Aug 2024
Results posted
No

Questions about this trial

What is this clinical trial studying?

A study testing Fat graft with Platelet Rich Plasma in people with Tympanic Membrane Perforation, run by Nova Scotia Health Authority at 4 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 21 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Canada, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Presence or absence of tympanic membrane perforation (time frame: 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in